Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.

@article{Yeilding2011DevelopmentOT,
  title={Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives.},
  author={Newman Yeilding and Philippe O. Szapary and Carrie Brodmerkel and Jacqueline M. Benson and Michael I. Plotnick and Honghui Zhou and Kavitha Goyal and Brad Schenkel and Jill Giles-Komar and Mary Ann Mascelli and Cynthia Guzzo},
  journal={Annals of the New York Academy of Sciences},
  year={2011},
  volume={1222},
  pages={
          30-9
        }
}
The development of ustekinumab as a first-in-class anti-interleukin (IL) 12/23p40 therapeutic agent for psoriasis represents an important example of modern and rational drug design and development. Psoriasis is a chronic, systemic, immune-mediated skin disorder with considerable clinical, psychosocial, and economic burden. Ustekinumab is a human monoclonal antibody (mAb) that binds the p40 subunit common to IL-12 and IL-23, key cytokines in psoriasis pathogenesis. The therapeutic mAb was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS